Company
Axogen
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
6
As lead sponsor, any status
Adverse event reports
23
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
AXGN
Nasdaq · Axogen, Inc.
Public float
$431M
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$225M
Fiscal year ending Dec 31, 2025
Net income
-$15.7M
Fiscal year ending Dec 31, 2025
R&D spending
$32.9M
Fiscal year ending Dec 31, 2025
Cash
$329M
As of Sep 30, 2026
Long-term debt
$0
As of Sep 30, 2026
Shares outstanding
59.7M
As of Oct 26, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2021 | – | – | $15.0M | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Sep 30, 2011 | Equity Issued in a merger or acquisition; not counted as money raised | $1.0M | $1.0M | 11 | Rule 506 | Form D ↗Oct 13, 2011 |
| May 3, 2011 | Debt Issued in a merger or acquisition; not counted as money raised | $3.0M | $5.5M | 13 | Rule 506 | Form D/A ↗Jun 15, 20111 amendment |
| Jun 11, 2010 | Convertible note | $3.7M | $3.7M | 11 | Rule 506 | Form D/A ↗Jan 12, 20111 amendment |
1 more funding rounds with a free account
Company details
From the company's latest Form D.
- Legal name
- AxoGen, Inc.; AXOGEN CORP
- Headquarters
- Texarkana, Texas
- Incorporated
- Minnesota over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Other Health Care
- SEC filer
- CIK 805928 ↗, CIK 1358347 ↗
Executives, directors and promoters
As listed on the latest Form D.
11 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
K231708 · Decided Oct 12, 2023 · 122 days after receipt
Device type: Cuff, Nerve (JXI) · Neurology & Neurosurgery
K223640 · Decided Apr 7, 2023 · 123 days after receipt
Device type: Cuff, Nerve (JXI) · Neurology & Neurosurgery
- AxoGen Nerve Cap510(k)
K163446 · Decided Aug 8, 2017 · 243 days after receipt
Device type: Cuff, Nerve (JXI) · Neurology & Neurosurgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT06117501 · 19 participants · Start Oct 19, 2023 · Primary completion Aug 17, 2026
Device: Axoguard HA+ Nerve Protector™ · For: Recurrent Cubital Tunnel Syndrome; Recalcitrant Cubital Tunnel Syndrome
Sites: Tampa, Florida; Savannah, Georgia; Indianapolis, Indiana · 7 sites in all
- Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve EndsActive, not recruiting
NCT04865679 · 15 participants (planned) · Start Mar 2, 2022 · Primary completion Dec 2026
Device: Axoguard Nerve Cap® · For: Symptomatic Neuroma; Amputation; Chronic Nerve Pain
Sites: Boston, Massachusetts; Lubbock, Texas
- Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve ReconstructionActive, not recruiting
NCT01526681 · 3,126 participants · Start Nov 2008 · Primary completion Nov 2028
Device: Nerve Tube Conduit · For: Peripheral Nerve Injuries
Sites: Phoenix, Arizona; Orange, California; San Francisco, California · 49 sites in all
3 more trials with a free account
Reports received
23
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
0.0% of reports
Injury reports
23
100% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 1 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 1 | 0 | 0 |
| Jun 24 | 0 | 1 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 1 | 0 | 0 |
| Sep 24 | 0 | 1 | 0 | 0 |
| Oct 24 | 0 | 1 | 0 | 0 |
| Nov 24 | 0 | 3 | 0 | 0 |
| Dec 24 | 0 | 1 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 1 | 0 | 0 |
| May 25 | 0 | 3 | 0 | 0 |
| Jun 25 | 0 | 1 | 0 | 0 |
| Jul 25 | 0 | 1 | 0 | 0 |
| Aug 25 | 0 | 1 | 0 | 0 |
| Sep 25 | 0 | 3 | 0 | 0 |
| Oct 25 | 0 | 3 | 0 | 0 |
| Nov 25 | 0 | 2 | 0 | 0 |
| Dec 25 | 0 | 2 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 1 | 0 | 0 |
| Mar 26 | 0 | 1 | 0 | 0 |
| Apr 26 | 0 | 3 | 0 | 0 |
| May 26 | 0 | 2 | 0 | 0 |
| Jun 26 | 0 | 3 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 7 | 0 | 0 |
| Oct 26 | 0 | 2 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.